MK-4409

MK-4409
Clinical data
ATC code	None;
Legal status
Legal status	US: Investigational New Drug ;
Identifiers
	IUPAC name 2-[5-[5-(5-Chloropyridin-2-yl)sulfanyl-2-(4-fluorophenyl)-1,3-oxazol-4-yl]pyridin-2-yl]propan-2-ol;
CAS Number	1207745-58-1;
PubChem CID	53341130;
ChemSpider	25069631;
ChEMBL	ChEMBL1812717;
Chemical and physical data
Formula	C22H17FN3O2S
Molar mass	406.46 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES c3nc(C(O)(C)C)ccc3-c1nc(-c4ccc(F)cc4)oc1Sc(nc2)ccc2Cl;
	InChI InChI=1S/C22H17ClFN3O2S/c1-22(2,28)17-9-5-14(11-25-17)19-21(30-18-10-6-15(23)12-26-18)29-20(27-19)13-3-7-16(24)8-4-13/h3-12,28H,1-2H3; Key:DBZMCSVIITXLCC-UHFFFAOYSA-N;

MK-4409 is an experimental drug which acts as a potent and selective inhibitor of the enzyme fatty acid amide hydrolase (FAAH), with an IC₅₀ of 11 nM, and both analgesic and antiinflammatory effects in animal studies. It was studied for the treatment of neuropathic pain and progressed to early stage human clinical trials by 2009.[1][2]

References

Chobanian, Harry R.; Guo, Yan; Liu, Ping; Chioda, Marc D.; Fung, Selena; Lanza, Thomas J.; Chang, Linda; Bakshi, Raman K.; Dellureficio, James P.; Hong, Qingmei; McLaughlin, Mark; Belyk, Kevin M.; Krska, Shane W.; Makarewicz, Amanda K.; Martel, Elliot J.; Leone, Joseph F.; Frey, Lisa; Karanam, Bindhu; Madeira, Maria; Alvaro, Raul; Shuman, Joyce; Salituro, Gino; Terebetski, Jenna L.; Jochnowitz, Nina; Mistry, Shruti; McGowan, Erin; Hajdu, Richard; Rosenbach, Mark; Abbadie, Catherine; et al. (2014). "Discovery of MK-4409, a Novel Oxazole FAAH Inhibitor for the Treatment of Inflammatory and Neuropathic Pain". ACS Medicinal Chemistry Letters. 5 (6): 717–721. doi:10.1021/ml5001239. PMC 4060928. PMID 24944750.
Merck (15 October 2009). "Merck Pipeline, Oct 2009" (PDF). Merck.

External links

MK 4409, Adis Insight

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[1] Chobanian, Harry R.; Guo, Yan; Liu, Ping; Chioda, Marc D.; Fung, Selena; Lanza, Thomas J.; Chang, Linda; Bakshi, Raman K.; Dellureficio, James P.; Hong, Qingmei; McLaughlin, Mark; Belyk, Kevin M.; Krska, Shane W.; Makarewicz, Amanda K.; Martel, Elliot J.; Leone, Joseph F.; Frey, Lisa; Karanam, Bindhu; Madeira, Maria; Alvaro, Raul; Shuman, Joyce; Salituro, Gino; Terebetski, Jenna L.; Jochnowitz, Nina; Mistry, Shruti; McGowan, Erin; Hajdu, Richard; Rosenbach, Mark; Abbadie, Catherine; et al. (2014). "Discovery of MK-4409, a Novel Oxazole FAAH Inhibitor for the Treatment of Inflammatory and Neuropathic Pain". ACS Medicinal Chemistry Letters. 5 (6): 717–721. doi:10.1021/ml5001239. PMC 4060928. PMID 24944750.

[2] Merck (15 October 2009). "Merck Pipeline, Oct 2009" (PDF). Merck.

MK-4409

See also

References

External links